Randall LM, O'Malley DM, Monk BJ, Coleman RL, et al. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032). Gynecol Oncol 2023;178:161-169.
PMID: 37890345